Why Functional Medicine Is the Future of Longevity

Bredesen developed the ReCODE protocol after realizing that Alzheimer's results from a network of insufficient systems, not a single cause. The protocol uses extensive lab testing to identify individual contributors (inflammation, insulin resistance, nutrient deficiencies, toxins, etc.) and then deploys targeted interventions—diet, exercise, sleep optimization, stress reduction, supplements, and sometimes medications—to address each one. The first patient treated in 2012 improved dramatically and remains well. Since then, thousands have been treated, with documented improvements. A proof-of-concept trial published in 2022 showed benefit, and an independent replication by Dr. Heather Sanderson confirmed the results. The ongoing RCT is the next level of evidence. Bredesen stresses that this approach is not anti-medication; he envisions combining targeted drugs with the protocol for even greater effect.

Charles Serhan's work shows that the resolution of inflammation is an active process requiring EPA and DHA to produce resolvins, protectins, and maresins. These molecules stimulate macrophage clearance of dead cells and debris. Without adequate omega-3s, the resolution phase is impaired, leading to chronic inflammation. Importantly, the body needs both omega-6 (arachidonic acid) for the initial inflammatory response and the class switch to lipoxins, and omega-3 for the later resolution mediators. Thus, the goal is balance, not elimination of omega-6. Serhan also notes that free fatty acids in circulation are the main source for SPMs in acute inflammation, so maintaining circulating levels is key.

Bob Roundtree recounts the story of Roy Walford, a pioneer in caloric restriction research, who participated in the Biosphere 2 experiment. Due to food shortages, the crew experienced severe calorie restriction. Initially, many health markers improved, but later, Walford's health declined, and his student Valter Longo noted that the severe restriction did not pay off in the long run. Roundtree also mentions that monkey studies have not consistently shown lifespan extension from severe calorie restriction. This serves as a caution that extreme interventions may not translate to human longevity and could be harmful.

Bob Roundtree explains that a mammalian clock using conserved CPG methylation sites can map life expectancy across species. Despite many longevity interventions being tested, none have successfully manipulated this clock. The authors, including Horvath, propose that this consistency points to a 'pseudo program'—a built-in aging trajectory that may be an active program rather than just accumulated damage. Roundtree finds this compelling evidence that there is an underlying programmatic phenomenon driving aging, which could explain why some supercentenarians seem to have a genetic advantage. He contrasts this with the idea of escape velocity, where one might reverse biological age every year, noting that the clock's resistance to change suggests a more complex reality.

Dale Bredesen describes how his 30 years of molecular research led him to see Alzheimer's as a network insufficiency. Evolution selects for high-performance brains but not durability, creating Achilles heels. When multiple stressors (inflammation, reduced blood flow, oxygenation, etc.) accumulate, the network downsizes. Depending on which part of the network fails, you get Alzheimer's (neuroplasticity loss), ALS (amplification loss), or Parkinson's (motor modulation loss). This insight forced him to abandon the single-drug approach and instead address all insufficient network pieces simultaneously, which became the ReCODE protocol. He notes that this conclusion, reached from test-tube research, converged with the functional medicine model developed from clinical experience.

Charles Serhan describes how his team studied pus from a mouse model of acute inflammation. They observed that as neutrophil infiltration peaked and began to decline, the lipid mediators produced by the immune cells underwent a class switch: from arachidonic acid-derived prostaglandins and leukotrienes (pro-inflammatory) to EPA- and DHA-derived resolvins, protectins, and maresins (pro-resolving). These SPMs not only stop further neutrophil recruitment but also stimulate macrophages to clear dead cells and debris (efferocytosis), returning the tissue to homeostasis. This is a highly orchestrated, active program, not a passive wind-down. The discovery has opened a new field of resolution pharmacology, distinct from anti-inflammation.

Serhan shares recent data from multiple labs showing that in the acute inflammatory response, the lion's share of EPA and DHA used to make resolvins, protectins, and maresins comes directly from free fatty acids in the circulation, bypassing the esterification step into phospholipids. However, in other contexts like vagus nerve stimulation, DHA appears to come from membrane phospholipid pools, and M2 reparative macrophages carry DHA in their plasma membranes to produce SPMs locally. This indicates two distinct systems: one rapid, using circulating free fatty acids, and another more localized, using membrane stores. This has implications for how we think about omega-3 supplementation and timing.

Serhan notes that aged mice show excessive inflammatory responses and a loss of resolution mediators, meaning they cannot counter-regulate inflammation. This loss of control is a key feature of aging. Excitingly, his group and others have shown that resolvins and SPM-stimulated M2 macrophages can clear senescent cells. This positions SPMs as potential senolytics that work with the body's own cleanup systems. Additionally, in the spleen, an EPA-derived resolvin E4 stimulates macrophages to clear aged red blood cells, a physiological process that maintains healthy blood cell turnover. These findings suggest that boosting SPMs could address multiple aging processes.

Dale Bredesen reports that the trial, led by several physicians, compares standard of care to a personalized functional medicine protocol. The standard-of-care group is declining as expected, while the protocol group is improving, with a statistically significant difference already achieved. The trial will be completed on October 31st and published next year. Bredesen also mentions that Dr. Heather Sanderson independently published a similar trial with very similar results, providing confirmation. He emphasizes that this is not an isolated finding—anyone who does this seriously sees improvements. The next steps include adapting the approach to other neurodegenerative diseases like macular degeneration, Lewy body disease, ALS, Parkinson's, and frontotemporal dementia.